. Author manuscript; available in PMC: 2019 Oct 1.

Published in final edited form as: Dis Colon Rectum. 2018 Oct;61(10):1146–1155. doi: 10.1097/DCR.0000000000001207

TABLE 2.

Chemotherapy by study group

Study group (n)	Neoadjuvant chemotherapy		Adjuvant chemotherapy		Any chemotherapy

	No. of patients (%)	No. of cycles^a	No. of patients (%)^b	No. of cycles^a	No. of patients (%)^b	Total no. of cycles^a

SG1 (40)	NA	0	22 (69)	4.9 ± 4.4	22 (69)	4.9 ± 4.4
SG2 (56)	50 (89)	1.8 ± 0.7	41 (80)	5.5 ± 3.4	51 (100)	7.3 ± 3.4
SG3 (53)	50 (94)	3.6 ± 1	34 (67)	3 ± 2.6	51 (100)	6.5 ± 2.4
SG4 (62)	54 (87)	5.1 ± 2	33 (55)	1.9 ± 2.4	58 (97)	7.1 ± 2.4

Mean ± SD.

Data on adjuvant chemotherapy were not available for 17 patients: 8 in SG1, 5 in SG2, 2 in SG3, and 2 in SG4. Therefore, the percentages are based on the total number of patients with complete data on adjuvant chemotherapy in each SG. NA, not available.